Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...
New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...
Gene expression testing, such as Oncotype DX, aids in chemotherapy decisions for hormone receptor-positive breast cancer, though challenges exist for premenopausal patients with scores under 25.
Breast cancer imposes a substantial disease burden on the Brazilian population. Furthermore, the potential unnecessary use of adjuvant chemotherapy exposes patients to risks and adverse effects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results